Herpes Zoster

Categories: Infectious diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Herpes Zoster

Summaries for Herpes Zoster

MedlinePlus: 41 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who: Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What other problems can shingles cause? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary: Herpes Zoster, also known as shingles, is related to exanthem and chickenpox, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is DPYD (Dihydropyrimidine Dehydrogenase), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Bupivacaine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include nerve fiber, skin and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and nervous system

MedlinePlus Genetics: 42 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50.Shingles is characterized by a severely painful, itchy, or tingling rash, most commonly on one side of the torso, although it can occur anywhere on the body. Reactivation of the virus usually occurs in a single nerve, leading to the symptoms of shingles in just the region of skin connected to that nerve. When the nerve connected to the eye and the skin surrounding it is affected, the condition is called herpes zoster ophthalmicus. This form of shingles, which accounts for about 20 percent of cases, can cause permanent vision impairment.Some individuals with shingles feel throbbing or tingling in the affected region shortly before the rash appears. Blisters form in the rash area, break open, and scab over in a few days. Healing usually takes 2 to 4 weeks. Most people have only one episode of shingles, although it can recur in rare cases.In 5 to 20 percent of people with shingles, severe pain continues in the affected region after healing of the rash, which is known as postherpetic neuralgia (PHN). PHN is the most common complication of shingles. It can also involve severe itchiness or an overactive pain response to things that do not usually cause pain (allodynia), such as a light touch. PHN can last weeks, months, or even years. The likelihood of developing PHN after shingles and its severity increase with age. The pain caused by shingles and PHN can disrupt day-to-day activities and reduce a person's quality of life.

NINDS: 52 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 63 Shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body. People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox. Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications. Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

CDC: 2 Shingles is a painful rash that usually develops on one side of the body, often the face or torso. The rash consists of blisters that typically scab over in 7 to 10 days and clears up within 2 to 4 weeks. Some people describe the pain as an intense burning sensation. For some people, the pain can last for months or even years after the rash goes away. This long-lasting pain is called postherpetic neuralgia (PHN), and it is the most common complication of shingles. Your risk of getting shingles and PHN increases as you get older. Two vaccines are licensed and recommended to prevent shingles in the U.S.. Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix), has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine

Disease Ontology: 11 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Wikipedia: 75 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Related Diseases for Herpes Zoster

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1376)
# Related Disease Score Top Affiliating Genes
1 exanthem 31.8 PDCD1 IL2 IL10 IFNG IFNA1 HLA-B
2 chickenpox 31.8 TLR3 IL2 IL10 IFNG IFNA1 GYPC
3 vasculitis 31.7 IL10 IFNA2 HLA-DRB1 HLA-B
4 neuritis 31.6 IL10 IFNG CCR5 APOE
5 encephalitis 31.6 TLR3 TLR2 IL10 IFNA1 CCR5
6 spondyloarthropathy 1 31.3 IL10 HLA-B CD8A
7 meningitis 31.3 TLR2 IL2 IL10 IFNG HLA-B
8 anterior uveitis 31.3 TLR2 IL2 IL10 IFNG HLA-DRB1 HLA-B
9 herpes simplex 31.3 TLR3 IFNA1 GYPC CD8A
10 covid-19 31.3 IL2 IL10 IFNA2 HLA-A
11 myositis 31.2 IFNG IFNA1 HLA-DRB1 HLA-B
12 psoriatic arthritis 31.2 TLR2 IL10 HLA-DRB1 HLA-B
13 uveitis 31.2 IL2 IL10 IFNG IFNA2 HLA-DRB1 HLA-B
14 spondylitis 31.2 IL10 IFNG HLA-DRB1 HLA-B
15 optic neuritis 31.1 IL10 HLA-DRB1 HLA-B HLA-A CCR5 APOE
16 aseptic meningitis 31.1 IL10 IFNA1 CD8A
17 iritis 31.1 IL10 HLA-B HLA-A CD8A
18 human immunodeficiency virus type 1 31.1 TLR3 IL2 IL10 IFNG HLA-B CCR5
19 graft-versus-host disease 31.1 IL2 IL10 IFNG
20 iridocyclitis 31.1 IL10 HLA-DRB1 HLA-B CD8A
21 conjunctivitis 31.0 TLR3 IL2 IL10 IFNG HLA-B
22 folliculitis 31.0 IL10 IFNG FCGR3A
23 arthritis 31.0 TRPV1 TLR2 IL2 IL10 IFNG HLA-DRB1
24 measles 31.0 TLR3 TLR2 IL2 IFNA1
25 severe acute respiratory syndrome 30.9 IL2 IL10 IFNG IFNA1 HLA-A
26 influenza 30.9 TLR3 IFNG IFNA1 HLA-B
27 ulcerative colitis 30.9 TLR2 IL2 IL10 IFNG HLA-DRB1
28 acute retinal necrosis syndrome 30.9 IL10 GYPC CD8A
29 pemphigoid 30.9 IL2 IL10 IFNG
30 lichen planus 30.9 IL2 IL10 IFNG
31 fasciitis 30.9 IL2 IFNG IFNA1
32 leukemia, chronic lymphocytic 30.9 PDCD1 IL2 IL10 IFNA1 FCGR3A CD8A
33 viral infectious disease 30.9 TLR3 TLR2 PDCD1 IL2 IL10 IFNG
34 allergic disease 30.9 IL2 IL10 IFNG CD8A
35 keratoconjunctivitis 30.8 IL2 IFNG CCR5
36 psoriasis 30.8 TLR2 IL2 IL10 IFNG HLA-DRB1 HLA-B
37 sarcoidosis 1 30.8 IL2 IL10 IFNG HLA-DRB1 HLA-A CD8A
38 purpura 30.8 IL2 IL10 IFNG HLA-DRB1
39 mumps 30.8 TLR3 IL2 IL10 IFNG IFNA1 HLA-DRB1
40 crohn's disease 30.8 TLR2 IL2 IL10 IFNG CD8A
41 pityriasis rosea 30.8 HLA-DRB1 HLA-B HLA-A CD8A
42 syphilis 30.8 TLR2 HLA-DRB1 CD8A CCR5
43 rubella 30.8 TLR3 IL2 IL10 IFNG HLA-DRB1 HLA-B
44 osteomyelitis 30.7 TLR2 IL10 IFNG
45 posterior uveitis 30.7 IL2 HLA-B HLA-A
46 acquired immunodeficiency syndrome 30.7 IL2 IL10 IFNG IFNA2 IFNA1 HLA-B
47 pharyngitis 30.7 TLR2 HLA-DRB1 CD8A
48 vaccinia 30.7 IL2 IFNA1 HLA-B CCR5
49 leishmaniasis 30.7 TLR2 IL2 IL10 IFNG CCR5
50 contact dermatitis 30.7 TLR2 IL2 IL10 IFNG CD8A

Graphical network of the top 20 diseases related to Herpes Zoster:

Diseases related to Herpes Zoster

Symptoms & Phenotypes for Herpes Zoster


  • fever
  • paresthesia
  • headache
  • malaise
  • itching
  • rash which is followed by blisters
  • burning pain

UMLS symptoms related to Herpes Zoster:

tremor; fever; back pain; angina pectoris; headache; pruritus; syncope; pain; chronic pain; sciatica; seizures; exanthema; vertigo/dizziness; equilibration disorder; sleeplessness

GenomeRNAi Phenotypes related to Herpes Zoster according to GeneCards Suite gene sharing:

25 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.11 APOE CCR5 CD8A DHFR DPYD FCGR3A
2 no effect GR00402-S-2 10.11 APOE CCR5 DHFR DPYD HCP5 HLA-A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10 IFNA1 IFNA2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10 IFNA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10 IFNA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-145 10 IFNA1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-167 10 IFNA2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10 IFNA1 IFNA2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-175 10 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10 IFNA2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-209 10 IFNA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10 IFNA2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10 IFNA2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10 IFNA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-62 10 IFNA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10 HLA-A HLA-B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10 IFNA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10 IFNA1

MGI Mouse Phenotypes related to Herpes Zoster:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.23 APOE CCR5 CD8A DHFR HLA-A HLA-B
2 neoplasm MP:0002006 10.1 CCR5 IFNG IL10 IL2 PDCD1 TLR2
3 no phenotypic analysis MP:0003012 10.08 APOE FCGR3A HLA-A HLA-B IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.07 APOE CD8A HLA-A HLA-B IFNG IL10
5 liver/biliary system MP:0005370 10.06 APOE CCR5 DHFR IFNG IL10 IL2
6 immune system MP:0005387 10.06 APOE CCR5 CD8A DHFR FCGR3A HLA-A
7 muscle MP:0005369 10.03 APOE CCR5 DHFR IFNG IL10 PDCD1
8 cardiovascular system MP:0005385 10 APOE CCR5 DHFR HLA-B IFNG IL10
9 digestive/alimentary MP:0005381 9.92 APOE CCR5 DPYD HLA-B IFNG IL10
10 respiratory system MP:0005388 9.65 APOE CCR5 IFNA1 IFNA2 IFNG IL10
11 hematopoietic system MP:0005397 9.53 APOE CCR5 CD8A DHFR FCGR3A GYPC

Drugs & Therapeutics for Herpes Zoster

PubMed Health treatment related to Herpes Zoster: 63

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin ). Prescription painkillers are sometimes used to relieve more severe pain. Thorough skin care is recommended if you have shingles . Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters . Most of them contain tanins, zinc , menthol or polidocanol . If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work. Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system , if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy ." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion ). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
Ethanol Approved Phase 4 64-17-5 702
Vedolizumab Approved Phase 4 943609-66-3
Carbamide peroxide Approved Phase 4 124-43-6
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
12 Janus Kinase Inhibitors Phase 4
13 Neurotransmitter Agents Phase 4
14 Psychotropic Drugs Phase 4
15 Hormones Phase 4
16 Calcium, Dietary Phase 4
17 Anti-Anxiety Agents Phase 4
18 Excitatory Amino Acid Antagonists Phase 4
19 Anticonvulsants Phase 4
20 calcium channel blockers Phase 4
21 Reverse Transcriptase Inhibitors Phase 4
22 Respiratory System Agents Phase 4
23 Bronchodilator Agents Phase 4
24 Anti-Asthmatic Agents Phase 4
25 Hormone Antagonists Phase 4
26 glucocorticoids Phase 4
27 Anti-Inflammatory Agents Phase 4
28 Immunologic Factors Phase 4
29 Immunoglobulins Phase 4
30 Antibodies Phase 4
31 Immunosuppressive Agents Phase 4
32 Potassium phosphate Phase 4
33 polysaccharide-K Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Methylene blue Approved, Investigational Phase 3 61-73-4 6099
Acyclovir Approved Phase 3 59277-89-3 2022
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
Capsaicin Approved Phase 3 404-86-4 1548943
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
Methadone Approved Phase 3 76-99-3, 1095-90-5 4095
Nortriptyline Approved Phase 3 72-69-5 4543
Desipramine Approved, Investigational Phase 3 50-47-5 2995
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Altretamine Approved Phase 3 645-05-6 2123
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
Sorivudine Investigational Phase 3 77181-69-2
50 Heptavalent Pneumococcal Conjugate Vaccine Phase 3

Interventional clinical trials:

(show top 50) (show all 301)
# Name Status NCT ID Phase Drugs
1 Ultrasound Guided Erector Spinae Block Versus Ultrasound Guided Thoracic Paravertebral Block for Pain Relief in Patients With Acute Thoracic Herpes Zoster Unknown status NCT04656821 Phase 4 Control Rx
2 The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Unknown status NCT03886038 Phase 4
3 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Unknown status NCT03016884 Phase 4
4 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Unknown status NCT03493776 Phase 4
5 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
6 Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
7 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Unknown status NCT03330171 Phase 4
8 Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
9 A Cross-over, Open-label, Single-group Study to Evaluate the Safety and Immunogenicity of Live Attenuated Varicella Vaccine Skyvaricella Injection (Inj.) Developed by SK Bioscience (Company Limited) Co., Ltd of South Korea in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old Unknown status NCT04384016 Phase 4
10 A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Unknown status NCT02444936 Phase 4 ZOSTAVAX
11 A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya. Unknown status NCT02514018 Phase 4
12 Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations Completed NCT00940940 Phase 4
13 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
14 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
15 A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China Completed NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
16 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
17 An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old. Completed NCT00681031 Phase 4
18 A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age Completed NCT00550745 Phase 4
19 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial Completed NCT03809702 Phase 4 Pregabalin;Placebo
20 T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape Completed NCT01911065 Phase 4
21 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
22 An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea Completed NCT01556451 Phase 4
23 A Randomized, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Inactivated Hepatitis A Vaccine Completed NCT05526820 Phase 4
24 Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina Completed NCT00830648 Phase 4
25 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
26 Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
27 Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
28 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
29 Immune Response to Shingles Vaccination Completed NCT02624375 Phase 4 Zoster Vaccine Live
30 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
31 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
32 A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
33 Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
34 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
35 A Clinical Trial to Evaluate Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Children Aged 1-12 Years Recruiting NCT05470855 Phase 4
36 A Randomized, Blind, Controlled Clinical Trial to Evaluate Safety and Immunogenicity of Live Attenuated Varicella Vaccine After a Two-dose Vaccination Course in Healthy Population Aged ≥13 Years Old Recruiting NCT05015686 Phase 4
37 Safety of Simultaneous Vaccination With Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV4) Recruiting NCT05007041 Phase 4
38 A Phase IV, Randomized, Observer-blind, Placebo-controlled, Multi-center Study to Assess the Prophylactic Efficacy Against Herpes Zoster, Immunogenicity and Safety of Shingrix When Administered Intramuscularly on a 2-dose Schedule in Chinese Adults Aged 50 Years and Older Active, not recruiting NCT04869982 Phase 4 Placebo
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Crossover Study Evaluating the Safety and Immunogenicity of the Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus Not yet recruiting NCT05559671 Phase 4
40 Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial Not yet recruiting NCT04748939 Phase 4
41 Immunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric Study Not yet recruiting NCT05596526 Phase 4
42 VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Not yet recruiting NCT04403139 Phase 4 Shingrix
43 An Open Clinical Trial to Evaluate the Immunity Persistence of Live Attenuated Varicella Vaccine at 5 and 8 Years After Primary Immunization With Live Attenuated Varicella Vaccine Not yet recruiting NCT05095701 Phase 4
44 An Open Clinical Trial to Evaluate Immunogenicity,Safety and Protective Effect of Live Attenuated Varicella Vaccine and a Clinical Trial on Antibody Level and Etiology of Varicella Zoster Virus in Zhejiang Province Not yet recruiting NCT05460429 Phase 4
45 Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter Study Not yet recruiting NCT05575830 Phase 4
46 Safety and Immunogenicity of Recombinant Glycoprotein E Herpes Zoster Subunit (HZ/su) Vaccine in Renal Transplant Recipients Suspended NCT03993717 Phase 4
47 A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy Terminated NCT02408159 Phase 4 Varicella Zoster Vaccine;Placebo
48 Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Withdrawn NCT02026089 Phase 4
49 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
50 Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery Unknown status NCT00926419 Phase 2, Phase 3

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Acyclovir Sodium
Capsicum extract
Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes zoster

Genetic Tests for Herpes Zoster

Anatomical Context for Herpes Zoster

Organs/tissues related to Herpes Zoster:

FMA: Nerve Fiber
MalaCards : Skin, T Cells, Eye, Bone Marrow, Brain, Liver, Kidney

Publications for Herpes Zoster

Articles related to Herpes Zoster:

(show top 50) (show all 20270)
# Title Authors PMID Year
Willingness to accept herpes zoster vaccines and the influencing factors in China. 62 41
36435780 2022
A typical case of herpes zoster on lower limb. 62 41
36451987 2022
Comparison of Adjuvant Hypertonic Saline and Normal Saline for Epidural Block in Patients with Postherpetic Neuralgia: A Double-Blind, Randomized Trial. 62 41
36451915 2022
Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. 53 62
14593495 2005
[Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus]. 53 62
12604384 2003
Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. 53 62
10027650 1999
Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB. 53 62
9207378 1997
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. 53 62
9164418 1997
Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. 53 62
8549030 1996
Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. 53 62
8553555 1995
Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine. 53 62
7486953 1995
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine. 53 62
8045919 1994
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 53 62
1569421 1992
[Therapeutic indications in herpes zoster]. 53 62
1828198 1991
Structured Imaging Approach for Viral Encephalitis. 62
36404046 2023
A Guide to Preclinical Models of Zoster-Associated Pain and Postherpetic Neuralgia. 62
34524508 2023
Viral infections in pediatric brain tumor patients treated with targeted therapies. 62
36308741 2023
Common Features Between Stroke Following Varicella in Children and Stroke Following Herpes Zoster in Adults : Varicella-Zoster Virus in Trigeminal Ganglion. 62
34224015 2023
Humanized Severe Combined Immunodeficient (SCID) Mouse Models for Varicella-Zoster Virus Pathogenesis. 62
35292858 2023
Modulation of Host Cell Signaling Pathways by Varicella-Zoster Virus. 62
35624345 2023
Modulation of Apoptosis and Cell Death Pathways by Varicella-Zoster Virus. 62
35624346 2023
Varicella-Zoster Virus-Genetics, Molecular Evolution and Recombination. 62
34374828 2023
Modulation of MHC and MHC-Like Molecules by Varicella Zoster Virus. 62
35332385 2023
Varicella Zoster Virus Neuronal Latency and Reactivation Modeled in Vitro. 62
34904194 2023
Immune Responses to Varicella-Zoster Virus Vaccines. 62
35102438 2023
Effective treatment of high-voltage pulsed radiofrequency combined with oxygen-ozone injection in acute zoster neuralgia. 62
36334554 2022
Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy. 62
35982184 2022
Risk Factors for Poor Pain Control in Zoster-Associated Pain: A Retrospective Study. 62
36030333 2022
Improving older adults' vaccination uptake: Are existing measures of vaccine hesitancy valid and reliable for older people? 62
35410504 2022
Shoulder Injury Related to Zoster Vaccine Administration. 62
35491135 2022
Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children. 62
36151963 2022
Comparison of Two Different Pulsed Radiofrequency Modes for Prevention of Postherpetic Neuralgia in Elderly Patients With Acute/Subacute Trigeminal Herpes Zoster. 62
34008278 2022
Herpes zoster und kardiovaskuläre Ereignisse : Protektiver Effekt von antiviraler Systemtherapie und Impfung. 62
36427085 2022
Herpes zoster: A primary care approach to diagnosis and treatment. 62
36346926 2022
Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation. 62
36379753 2022
Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States. 62
35049412 2022
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. 62
36255569 2022
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. 62
36207461 2022
A Case of Orbital Apex Syndrome as a Complication of Herpes Zoster Ophthalmicus. 62
36413452 2022
Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: A retrospective United States claims database analysis. 62
36415956 2022
A case of herpes zoster ophthalmicus with optic neuritis of the total length of the optic nerve in the orbital space and ischemic optic neuropathy. 62
36467120 2022
Hospitalizations for infections in primary Sjögren's syndrome patients: a nationwide incidence study. 62
36173925 2022
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. 62
35973806 2022
Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis. 62
36459252 2022
Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. 62
36036539 2022
A prospective randomized comparison of the efficacy of standard antiviral therapy versus ultrasound-guided thoracic paravertebral block for acute herpes zoster. 62
35107389 2022
Epidemiology of Varicella Zoster Virus and Herpes Zoster Virus in Gulf Cooperation Council Countries: A Review of the Literature. 62
36460839 2022
Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials. 62
36322332 2022
Varicella Vaccine-Induced Infantile Zoster-Like Skin Rash. 62
36027973 2022
Herpes Zoster and Long-Term Risk of Cardiovascular Disease. 62
36382961 2022

Variations for Herpes Zoster

Expression for Herpes Zoster

Search GEO for disease gene expression data for Herpes Zoster.

Pathways for Herpes Zoster

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11 12.05 HLA-B HLA-A FCGR3A CD8A
12 11.96 CD8A IFNA2 IFNG IL10 IL2
Show member pathways
Show member pathways
11.85 TLR3 TLR2 IL2 IL10 IFNG
Show member pathways
11.83 TLR3 TLR2 IFNA2
Show member pathways
11.81 TLR3 TLR2 IFNG
17 11.81 IFNG IFNA2 IFNA1
Show member pathways
19 11.78 IL2 IL10 IFNG CD8A
20 11.74 TLR3 TLR2 PDCD1 IL2 IL10 IFNG
21 11.72 PDCD1 IL2 IL10 IFNG
22 11.69 HLA-A IFNG IL10 IL2
Show member pathways
11.61 TLR2 IL2 IL10 IFNG
24 11.59 TLR3 IL2 IL10 IFNG CCR5
25 11.52 CD8A IFNA2 IFNG IL10 IL2
26 11.51 IL2 IL10 IFNG HLA-DRB1
27 11.49 IL2 IL10 IFNG
29 11.39 HLA-DRB1 HLA-B HLA-A
30 11.38 IFNG IFNA2 HLA-B
31 11.37 IL10 HLA-DRB1 FCGR3A
Show member pathways
11.36 IL2 IL10 IFNG
33 11.21 IFNG IL10 IL2
34 11.2 IL2 IL10 IFNG HLA-DRB1
35 11.19 PDCD1 IL2 CD8A
36 11.18 IL2 IL10 IFNG
37 11.12 PDCD1 IFNG CD8A
38 10.91 IL2 IFNG CCR5
39 10.66 IL2 IFNG
40 10.61 TLR2 APOE

GO Terms for Herpes Zoster

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.93 TRPV1 PDCD1 HLA-DRB1 FCGR3A CD8A CCR5
2 plasma membrane GO:0005887 9.78 CCR5 CD8A FCGR3A GYPC HLA-A HLA-B
3 plasma membrane GO:0005886 9.78 CCR5 CD8A FCGR3A GYPC HLA-A HLA-B
4 obsolete integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-B HLA-A

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 10.25 IFNA1 IFNA2 IFNG TLR2 TLR3
2 cell surface receptor signaling pathway GO:0007166 10.23 CCR5 CD8A FCGR3A IFNA2 IFNG TRPV1
3 positive regulation of inflammatory response GO:0050729 10.16 TLR3 TLR2 IL2 IFNG
4 positive regulation of tumor necrosis factor production GO:0032760 10.14 TLR3 TLR2 IFNG FCGR3A
5 cellular response to virus GO:0098586 10.1 TLR3 IFNG IFNA2 IFNA1
6 B cell proliferation GO:0042100 10.09 IL10 IFNA2 IFNA1
7 positive regulation of chemokine production GO:0032722 10.08 TLR3 TLR2 IFNG
8 positive regulation of interleukin-12 production GO:0032735 10.07 TLR3 TLR2 IFNG
9 response to exogenous dsRNA GO:0043330 10.05 TLR3 IFNA2 IFNA1
10 positive regulation of T cell mediated cytotoxicity GO:0001916 9.99 HLA-A HLA-B HLA-DRB1
11 humoral immune response GO:0006959 9.96 PDCD1 IFNG IFNA2 IFNA1 HLA-DRB1
12 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.95 IFNG IFNA2 IFNA1
13 microglial cell activation GO:0001774 9.92 TRPV1 TLR3 TLR2 IFNG
14 protection from natural killer cell mediated cytotoxicity GO:0042270 9.91 HLA-B HLA-A
15 detection of bacterium GO:0016045 9.91 HLA-DRB1 HLA-B HLA-A
16 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.88 HLA-A HLA-B
17 defense response GO:0006952 9.88 TLR3 IFNA2 IFNA1 HLA-B CCR5
18 positive regulation of toll-like receptor signaling pathway GO:0034123 9.87 TLR3 TLR2
19 adaptive immune response GO:0002250 9.86 PDCD1 IL2 IFNG IFNA2 IFNA1 HLA-DRB1
20 positive regulation of plasma cell differentiation GO:1900100 9.83 IL2 IL10
21 immune system process GO:0002376 9.81 CD8A FCGR3A HLA-A HLA-B HLA-DRB1 IL2
22 antigen processing and presentation GO:0019882 9.77 CD8A HLA-A HLA-B HLA-DRB1
23 immune response GO:0006955 9.6 TLR3 TLR2 IL2 IL10 IFNG HLA-DRB1

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.65 IL2 IL10 IFNG IFNA2 IFNA1
2 peptide antigen binding GO:0042605 9.63 HLA-DRB1 HLA-B HLA-A
3 TAP binding GO:0046977 8.92 HLA-B HLA-A

Sources for Herpes Zoster

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....